###begin article-title 0
Pituitary-hormone secretion by thyrotropinomas
###end article-title 0
###begin p 1
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 895 903 <span type="species:ncbi:9606">patients</span>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
###xml 1082 1089 <span type="species:ncbi:9606">patient</span>
###xml 1173 1181 <span type="species:ncbi:9606">patients</span>
###xml 1291 1298 <span type="species:ncbi:9606">patient</span>
###xml 1308 1316 <span type="species:ncbi:9606">patients</span>
###xml 1462 1470 <span type="species:ncbi:9606">patients</span>
###xml 1526 1534 <span type="species:ncbi:9606">patients</span>
Hormone secretion by somatotropinomas, corticotropinomas and prolactinomas exhibits increased pulse frequency, basal and pulsatile secretion, accompanied by greater disorderliness. Increased concentrations of growth hormone (GH) or prolactin (PRL) are observed in about 30% of thyrotropinomas leading to acromegaly or disturbed sexual functions beyond thyrotropin (TSH)-induced hyperthyroidism. Regulation of non-TSH pituitary hormones in this context is not well understood. We there therefore evaluated TSH, GH and PRL secretion in 6 patients with up-to-date analytical and mathematical tools by 24-h blood sampling at 10-min intervals in a clinical research laboratory. The profiles were analyzed with a new deconvolution method, approximate entropy, cross-approximate entropy, cross-correlation and cosinor regression. TSH burst frequency and basal and pulsatile secretion were increased in patients compared with controls. TSH secretion patterns in patients were more irregular, but the diurnal rhythm was preserved at a higher mean with a 2.5 h phase delay. Although only one patient had clinical acromegaly, GH secretion and IGF-I levels were increased in two other patients and all three had a significant cross-correlation between the GH and TSH. PRL secretion was increased in one patient, but all patients had a significant cross-correlation with TSH and showed decreased PRL regularity. Cross-ApEn synchrony between TSH and GH did not differ between patients and controls, but TSH and PRL synchrony was reduced in patients. We conclude that TSH secretion by thyrotropinomas shares many characteristics of other pituitary hormone-secreting adenomas. In addition, abnormalities in GH and PRL secretion exist ranging from decreased (joint) regularity to overt hypersecretion, although not always clinically obvious, suggesting tumoral transformation of thyrotrope lineage cells.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1324 1325 1324 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 881 888 <span type="species:ncbi:9606">patient</span>
The major regulators of thyrotropin (TSH) secretion are thyrotropin-releasing hormone (TRH), the inhibitory neurotransmitters dopamine and somatostatin, and negative feed back by thyroid hormones, thyroxine and triiodothyronine [1]. The interplay among these regulators in time dictates the TSH secretion pattern, which is characterized by a diurnal variation of serum TSH concentrations with superimposed (small) bursts. The 24-h secretion profile of TSH has been well described in various pathophysiological conditions, including hyperthyroidism, hypothyroidism, obesity, fasting and in non-thyroidal illness, but not in detail in hyperthyroidism caused by a pituitary TSH-secreting adenomas [2-6]. TSH-secreting adenomas are relatively rare pituitary tumors (less than 1% of all pituitary adenomas), and are usually diagnosed when the TSH level is inappropriately elevated in a patient with raised serum thyroxine levels, combined with the presence of a pituitary (micro) adenoma [7]. In other hormone-secreting pituitary adenomas, e.g. Cushing's disease and prolactinomas, hormone secretion is marked by diminished or absent diurnal amplitude (one-half the difference between maximal and minimal concentrations), increased basal (i.e. non-pulsatile) secretion, elevated pulse frequency and reduced secretory regularity [8-10].
###end p 4
###begin p 5
###xml 464 465 460 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 712 720 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
###xml 996 1004 <span type="species:ncbi:9606">patients</span>
By analogy with results obtained in other hormone-secreting pituitary adenomas, we hypothesized that patients with thyrotropinomas would display a blunted diurnal secretion pattern, heightened basal and pulsatile TSH release, increased pulse frequency and attenuated regularity. Moreover, TSH adenomas may co-secrete other pituitary hormones, most frequently growth hormone and in decreasing order prolactin and gonadotropins, as well as uncombined alpha-subunit [7]. To examine the mechanistic secretory similarities between TSH and co-secreted hormones, we quantitated correlations between hormone concentration time series (TSH, GH, prolactin and alpha-subunit) using selected model-free tools. Finally, many patients with thyrotropinomas are currently treated with slow-release somatostatin analog formulations. Therefore we also explored the changes in fasting hormone levels in patients treated with long-acting somatostatin analogs. To this end serum hormone concentration profiles of six patients with thyrotropinomas were compared with those of 18 healthy controls that were investigated in a strictly comparable way.
###end p 5
###begin title 6
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 6
###begin p 7
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
Six patients (4 m/2 f) with central hyperthyroidism caused by a TSH-secreting adenoma and 18 healthy non-obese (BMI 18-25 kg/m2) control subjects of similar sex (12 m/6 f) and age distribution were enrolled in this study, after giving written acknowledgment of informed consent for participation. All premenopausal controls were required to have a regular menstrual cycle and not use oral contraceptives. Female subjects were studied in the early follicular phase of their menstrual cycle. Chronic disease, depression (present or in history), smoking, recent transmeridional flights, night shift work, weight change (>3 kg in 3 months), and use of medication (except for the patients) were exclusion criteria. All control subjects had an unremarkable medical history, and no abnormalities were found during physical examination, standard laboratory hematology, and blood chemistry and urine tests.
###end p 7
###begin title 8
Clinical protocol
###end title 8
###begin p 9
###xml 780 788 <span type="species:ncbi:9606">patients</span>
The protocol was approved by the Medical Ethics Committee of the Leiden University Medical Center (Leiden, The Netherlands). Subjects were admitted to the Clinical Research Unit of the Department of Internal Medicine. A cannula for blood sampling was inserted into an antecubital vein. The cannula was attached to a three-way stopcock and kept patent by a continuous saline infusion. Blood samples were taken at 10-min intervals for determination of plasma TSH, GH, prolactin and alpha-subunit concentrations. Subjects remained recumbent, except for bathroom visits. No daytime naps were allowed. Meals were served according to a fixed time schedule. Lights were switched off at 2300 h. Vital signs were recorded at regular time intervals, and great care was taken not to disturb patients while sampling blood during their sleep (no electroencephalography sleep recording was performed).
###end p 9
###begin title 10
Assays
###end title 10
###begin p 11
###xml 649 650 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 654 655 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
Samples were centrifuged at 4000 rotations/min at 4degreesC for 20 min, within 60 min of sampling. Subsequently, plasma was divided into separate aliquots and frozen at -80degreesC until assays were performed. Samples of each subject were determined in the same assay run. Plasma TSH concentrations were measured with a time-resolved immunofluorometric assay (Wallac, Turku, Finland), and its standard was calibrated against the World Health Organization second standard International Reference Preparation (80/558) hTSH for immunoassays. The limit of detection was 0.05 mU/liter, and the interassay coefficient of variation was less then 5%. Free T4 (fT4) was estimated using an automated system (Elecsys 2010, Roche Diagnostics Nederland BV, Almere, Netherlands). Triiodothyronine was measured with Abbott Axsym (Abbott Park, IL).
###end p 11
###begin p 12
###xml 178 183 <span type="species:ncbi:9606">human</span>
GH was measured with a sensitive time-resolved fluoro-immunoassay (Wallac Oy, Turku, Finland). The assay is specific for the 22 kDa GH. The standard was biosynthetic recombinant human GH (Genotropin, Pharmacia & Upjohn, Uppsala, Sweden), and was calibrated against the WHO First International Reference Preparation 80/505 (to convert mug/l to mU/l multiply by 2.6). The limit of detection of this assay (defined as the value 2SD above the mean value of the zero standards) was 0.01 mU/l (0.0038 ng/ml). The intraassay coefficient of variation varied between 1.6 and 8.4% in the range from 0.01 to 18 mug/l and interassay coefficient of variation was 2.0-9.0% in the same range.
###end p 12
###begin p 13
Total IGF-I was determined by RIA (Incstar, Stillwater, MN) after extraction and purification on ODS-silica columns. The intraassay coefficient of variation was less than 11%. The detection limit was 1.5 nmol/l. Age-related normal data were determined in the same laboratory.
###end p 13
###begin p 14
Plasma PRL concentration was measured with a sensitive time-resolved fluoroimmunoassay with a detection limit of 0.04 mug/l (Delfia, Wallac Oy, Turku, Finland). The intra-assay coefficient of variation varied from 2.0 to 3.3% and inter-assay coefficient of variation is 3.4-6.2%, in the concentration range from 3.0 to 80 mug/l.
###end p 14
###begin p 15
The alpha-subunits were measured by an immunoradiometric assay (Immunotech, Marseille, France). The assay is calibrated with WHO International Reference Preparation 75/569, and 1 mU is equivalent to 1 mug. The intra-assay coefficient of variation was 6.8% and the inter-assay coefficient of variation 9.1% in the concentration range observed here.
###end p 15
###begin title 16
Calculations and statistics
###end title 16
###begin title 17
Deconvolution analysis
###end title 17
###begin p 18
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 607 608 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 632 633 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 640 641 629 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 735 736 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 741 742 726 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 780 781 761 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 823 830 800 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#949;</sub>
###xml 881 882 849 850 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 888 889 853 854 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 895 896 857 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1019 1021 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1225 1231 1187 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lambda</italic>
###xml 1303 1308 1265 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gamma</italic>
###xml 1528 1530 1490 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
Each hormone concentration time series was analyzed using a recently validated deconvolution method [11]. The automated Matlab program first detrends the data and normalizes concentrations to the unit interval [0, 1]. Second, successive potential pulse-time sets, each containing one fewer burst, are created by a smoothing process (a nonlinear adaptation of the heat-diffusion equation). Third, a maximum-likelihood expectation (MLE) deconvolution method estimates all secretion and elimination rates simultaneously for each candidate pulse-time set. The deconvolution model specifies basal secretion (beta0), two half-lives (alpha1, alpha2), an accumulation process and weak interpulse length dependency for secretory-burst mass (eta0, eta1), random effects on burst mass (sigmaA), procedural and measurement error (sigmaepsilon), and a 3-parameter secretory-burst waveform (beta1, beta2, beta3). Model selection is performed to distinguish among the candidate pulse-time sets using the Akaike information criterion [12]. Observed interpulse intervals are described by a 2-parameter Weibull process (more general form of a Poisson renewal process). The parameters (and units) are frequency (number of bursts per unit time, lambda of Weibull distribution), regularity of interpulse intervals (unitless gamma of Weibull), slow half-life (min), basal and pulsatile secretion rates (concentration per unit time), mass secreted per burst (concentration), and waveform mode (time delay to maximal secretion after burst onset, min) [11].
###end p 18
###begin title 19
Approximate entropy (ApEn)
###end title 19
###begin p 20
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Approximate entropy, ApEn, is a scale-and model-independent univariate regularity statistic used to quantitate the orderliness (subpattern consistency) of serial stationary measurements [13, 14]. Mathematical models and feedback experiments establish that pattern orderliness monitors feedback and/or feedforward interactions within an interlinked axis with high sensitivity and specificity, both >90% [15]. Reduced pattern regularity typifies hormone secretion in puberty and aging, during diminished negative feedback or fixed exogenous stimulation, and by autonomous neuroendocrine tumors [16, 17]. Data are presented as normalized ApEn ratios, defined by the mean ratio of absolute ApEn to that of 1000 randomly shuffled versions of the same series. ApEn ratios close to 1.0 express high irregularity (mean randomness) of pulsatile hormone patterns.
###end p 20
###begin p 21
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1315 1317 1315 1317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1319 1321 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
Cross-Approximate Entropy (X-ApEn) is a scale- and model-independent two-variable regularity statistic used to quantitate the relative pattern synchrony of coupled time series [18, 19]. Clinical experiments establish that changes in two-hormone synchrony monitor feedback and/or feedforward adaptations within an interlinked axis with high sensitivity and specificity [15]. To normalize comparisons among subjects, X-ApEn is computed on the paired original time series (observed X-ApEn) and then recalculated 1000 times after each series in a pair is shuffled randomly [rearranged in order or sequence without replacement or loss (random X-ApEn). Repetition of the permutation procedure allows calculation of the maximum, mean, and SD of random X-ApEn for a given series length and assay pair. A normalized distributional measure is then the number of SDS (z scores) separating observed from the maximum or mean random X-ApEn. Higher absolute z scores denote more synchronous patterns. Lower X-ApEn ratios and higher absolute z scores denote greater pattern synchrony between (coordinate control of) the interlinked signals. Reduced regularity of hormone secretion typifies puberty, aging, diminished negative feedback due to target-gland failure, fixed exogenous stimulation, and autonomous neuroendocrine tumors [20, 21].
###end p 21
###begin title 22
Diurnal rhythmicity
###end title 22
###begin p 23
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
Nyctohemeral variation of TSH concentrations was determined by a nonlinear unweighted least-squares cosine regression, as reported earlier [22]. Ninety-five percent statistical confidence intervals were determined for the 24-h cosine amplitude (50% of the zenith-nadir difference), mesor (rhythmic mean) and acrophase (clock time of maximal value).
###end p 23
###begin title 24
Statistics
###end title 24
###begin p 25
###xml 184 185 182 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Data are presented as mean +/- SEM, unless otherwise specified. Means of TSH concentration and secretion parameters of both groups were compared using two-tailed independent Student's t-test after logarithmic transformation or with the Kolmogorov-Smirnov two-sample test. Conventional cross-correlations between hormone concentration series were calculated after prewhitening of the series by first differencing in order to prevent spurious correlations. Statistical calculations were performed with Systat software, version 11 (Systat Inc, San Jose, CA). Significance level was set at 0.05.
###end p 25
###begin title 26
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Clinical presentation of the patients
###end title 26
###begin p 27
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 1 was studied when he was 73 years old. His medical history revealed that he underwent thyroid surgery at the age of 53 yr because of presumed hyperthyroidism. After surgery he developed visual complaints and headaches and he was diagnosed with a large pituitary adenoma. He underwent pituitary surgery and because of incomplete resection pituitary irradiation as well. He was treated with thyroxine, testosterone supplements and cortisone acetate. For the pituitary tumor residue he received first bromocriptine, and later when immunostaining revealed beta-TSH, short-acting octreotide, 100 mug t.i.d. The 24-h blood sampling study was performed after withholding octreotide for 4 weeks. He is currently treated with octreotide-LAR, hydrocortisone, thyroxine and testosterone replacement.
###end p 27
###begin p 28
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 2, aged 44 years was referred of acromegaly and central hyperthyroidism. After detailed clinical studies and pretreatment with sc octreotide (100 mug t.i.d.) he underwent transsphenoidal adenomectomy leading to biochemical cure of the central hyperthyroidism, but insufficient control of GH secretion. He is currently treated with octreotide only.
###end p 28
###begin p 29
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 3, aged 38 years was evaluated at a teaching hospital because of weight loss and nervous symptoms. She was hyperthyroid, but TSH levels were not suppressed and MRI of the pituitary gland revealed a macroadenoma. For detailed endocrine studies she was referred to the Leiden University Medical Center. Subsequently, she was treated with octreotide LAR, with a favorable clinical response. After one year of treatment the 24-h blood sampling study was repeated.
###end p 29
###begin p 30
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 4, aged 26 years was referred because of long-standing nervousness, palpitations and excessive perspiration. He appeared to be hyperthyroid with non-suppressed TSH levels. Further studies revealed a pituitary adenoma and detailed biochemical studies, including a 24-h blood sampling were carried out. He was treated with octreotide LAR with good clinical response. After 3 years he underwent a repeat 24-h blood sampling study.
###end p 30
###begin p 31
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 187 194 <span type="species:ncbi:9606">patient</span>
Patient 5, aged 61 years was referred because of central hyperthyroidism and a pituitary microadenoma. Detailed biochemical studies were carried out, including a 24-h blood sampling. The patient, however, refused treatment. During infrequent follow-up visits for the last 12 years his clinical condition and TSH and thyroid hormone levels remained unchanged.
###end p 31
###begin p 32
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient 6, aged 60 years was medically treated in 1998 for hyperthyroidism in another hospital for one year. In 2006 she was reevaluated because of persisting hyperthyroid complaints, which were confirmed by biochemical analyses. In addition, the TSH levels were non-suppressed and the MRI of the pituitary gland revealed a macroadenoma. After the endocrine studies in our facility, treatment with octreotide LAR 20 mg was started. However, although TSH concentration decreased, T4 levels remained elevated, so that after 3 months the octreotide dose was increased to 30 mg/4 weeks without a clinical satisfactory response. Subsequently, it was found that she had a toxic nodular hyperthyroidism as well, for which was recently treated with strumazol and radioactive iodine (613 Mbq). Because of atrial fibrillation she was put on anticoagulant therapy and octreotide LAR was withheld.
###end p 32
###begin p 33
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 176 183 176 183 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 183 223 183 223 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Clinical characteristics of the patients</p>
###xml 183 223 183 223 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Clinical characteristics of the patients</p></caption>
###xml 223 230 223 230 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient</th>
###xml 230 236 230 236 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gender</th>
###xml 236 239 236 239 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age</th>
###xml 241 242 241 242 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 239 251 239 251 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">fT<sub>4</sub> (nmol/l)</th>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 251 262 251 262 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">T<sub>3</sub> (nmol/l)</th>
###xml 262 272 262 272 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TSH (mU/l)</th>
###xml 272 301 272 297 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#945;-Subunit/TSH molar ratio</th>
###xml 301 313 297 309 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Thyroid size</th>
###xml 313 326 309 322 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Pituitary MRI</th>
###xml 326 348 322 344 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Immunostaining adenoma</th>
###xml 223 348 223 344 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Patient</th><th align="left">Gender</th><th align="left">Age</th><th align="left">fT<sub>4</sub> (nmol/l)</th><th align="left">T<sub>3</sub> (nmol/l)</th><th align="left">TSH (mU/l)</th><th align="left">&#945;-Subunit/TSH molar ratio</th><th align="left">Thyroid size</th><th align="left">Pituitary MRI</th><th align="left">Immunostaining adenoma</th></tr>
###xml 223 348 223 344 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Patient</th><th align="left">Gender</th><th align="left">Age</th><th align="left">fT<sub>4</sub> (nmol/l)</th><th align="left">T<sub>3</sub> (nmol/l)</th><th align="left">TSH (mU/l)</th><th align="left">&#945;-Subunit/TSH molar ratio</th><th align="left">Thyroid size</th><th align="left">Pituitary MRI</th><th align="left">Immunostaining adenoma</th></tr></thead>
###xml 348 349 344 345 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 349 353 345 349 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 353 355 349 351 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">73</td>
###xml 355 357 351 353 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">31</td>
###xml 357 361 353 357 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.d.</td>
###xml 361 365 357 361 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.30</td>
###xml 365 369 361 365 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.99</td>
###xml 369 377 365 373 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 377 389 373 385 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Macroadenoma</td>
###xml 389 394 385 390 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TSH +</td>
###xml 348 394 344 390 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">Male</td><td char="." align="char">73</td><td char="." align="char">31</td><td align="left">n.d.</td><td char="." align="char">4.30</td><td char="." align="char">3.99</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">TSH +</td></tr>
###xml 394 395 390 391 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 395 399 391 395 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 399 401 395 397 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">44</td>
###xml 401 403 397 399 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">47</td>
###xml 403 406 399 402 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.1</td>
###xml 406 410 402 406 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.01</td>
###xml 410 414 406 410 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.80</td>
###xml 414 422 410 418 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 422 434 418 430 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Macroadenoma</td>
###xml 434 444 430 440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GH/TSH +/+</td>
###xml 394 444 390 440 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">Male</td><td char="." align="char">44</td><td char="." align="char">47</td><td align="left">4.1</td><td char="." align="char">3.01</td><td char="." align="char">7.80</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">GH/TSH +/+</td></tr>
###xml 444 445 440 441 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 445 451 441 447 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 451 453 447 449 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 453 455 449 451 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">36</td>
###xml 455 458 451 454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.2</td>
###xml 458 462 454 458 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.40</td>
###xml 462 466 458 462 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.30</td>
###xml 466 474 462 470 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 474 486 470 482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Macroadenoma</td>
###xml 486 489 482 485 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a</td>
###xml 444 489 440 485 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">Female</td><td char="." align="char">38</td><td char="." align="char">36</td><td align="left">3.2</td><td char="." align="char">1.40</td><td char="." align="char">1.30</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr>
###xml 489 490 485 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 490 494 486 490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 494 496 490 492 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 496 498 492 494 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 498 501 494 497 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4.2</td>
###xml 501 505 497 501 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.35</td>
###xml 505 509 501 505 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.93</td>
###xml 509 517 505 513 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 517 529 513 525 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Macroadenoma</td>
###xml 529 532 525 528 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a</td>
###xml 489 532 485 528 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">Male</td><td char="." align="char">26</td><td char="." align="char">30</td><td align="left">4.2</td><td char="." align="char">3.35</td><td char="." align="char">0.93</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr>
###xml 532 533 528 529 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 533 537 529 533 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 537 539 533 535 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61</td>
###xml 539 541 535 537 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">34</td>
###xml 541 544 537 540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.3</td>
###xml 544 548 540 544 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5.84</td>
###xml 548 552 544 548 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.62</td>
###xml 552 560 548 556 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 560 572 556 568 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Microadenoma</td>
###xml 572 575 568 571 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a</td>
###xml 532 575 528 571 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5</td><td align="left">Male</td><td char="." align="char">61</td><td char="." align="char">34</td><td align="left">3.3</td><td char="." align="char">5.84</td><td char="." align="char">0.62</td><td align="left">Enlarged</td><td align="left">Microadenoma</td><td align="left">n.a</td></tr>
###xml 575 576 571 572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 576 582 572 578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 582 584 578 580 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">60</td>
###xml 584 586 580 582 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 586 589 582 585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3.2</td>
###xml 589 593 585 589 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.01</td>
###xml 593 597 589 593 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.1</td>
###xml 597 605 593 601 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Enlarged</td>
###xml 605 617 601 613 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Macroadenoma</td>
###xml 617 620 613 616 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.a</td>
###xml 575 620 571 616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">Female</td><td char="." align="char">60</td><td char="." align="char">38</td><td align="left">3.2</td><td char="." align="char">1.01</td><td char="." align="char">14.1</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr>
###xml 348 620 344 616 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">1</td><td align="left">Male</td><td char="." align="char">73</td><td char="." align="char">31</td><td align="left">n.d.</td><td char="." align="char">4.30</td><td char="." align="char">3.99</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">TSH +</td></tr><tr><td align="left">2</td><td align="left">Male</td><td char="." align="char">44</td><td char="." align="char">47</td><td align="left">4.1</td><td char="." align="char">3.01</td><td char="." align="char">7.80</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">GH/TSH +/+</td></tr><tr><td align="left">3</td><td align="left">Female</td><td char="." align="char">38</td><td char="." align="char">36</td><td align="left">3.2</td><td char="." align="char">1.40</td><td char="." align="char">1.30</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">4</td><td align="left">Male</td><td char="." align="char">26</td><td char="." align="char">30</td><td align="left">4.2</td><td char="." align="char">3.35</td><td char="." align="char">0.93</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">5</td><td align="left">Male</td><td char="." align="char">61</td><td char="." align="char">34</td><td align="left">3.3</td><td char="." align="char">5.84</td><td char="." align="char">0.62</td><td align="left">Enlarged</td><td align="left">Microadenoma</td><td align="left">n.a</td></tr><tr><td align="left">6</td><td align="left">Female</td><td char="." align="char">60</td><td char="." align="char">38</td><td align="left">3.2</td><td char="." align="char">1.01</td><td char="." align="char">14.1</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr></tbody>
###xml 223 620 223 616 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Gender</th><th align="left">Age</th><th align="left">fT<sub>4</sub> (nmol/l)</th><th align="left">T<sub>3</sub> (nmol/l)</th><th align="left">TSH (mU/l)</th><th align="left">&#945;-Subunit/TSH molar ratio</th><th align="left">Thyroid size</th><th align="left">Pituitary MRI</th><th align="left">Immunostaining adenoma</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Male</td><td char="." align="char">73</td><td char="." align="char">31</td><td align="left">n.d.</td><td char="." align="char">4.30</td><td char="." align="char">3.99</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">TSH +</td></tr><tr><td align="left">2</td><td align="left">Male</td><td char="." align="char">44</td><td char="." align="char">47</td><td align="left">4.1</td><td char="." align="char">3.01</td><td char="." align="char">7.80</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">GH/TSH +/+</td></tr><tr><td align="left">3</td><td align="left">Female</td><td char="." align="char">38</td><td char="." align="char">36</td><td align="left">3.2</td><td char="." align="char">1.40</td><td char="." align="char">1.30</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">4</td><td align="left">Male</td><td char="." align="char">26</td><td char="." align="char">30</td><td align="left">4.2</td><td char="." align="char">3.35</td><td char="." align="char">0.93</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">5</td><td align="left">Male</td><td char="." align="char">61</td><td char="." align="char">34</td><td align="left">3.3</td><td char="." align="char">5.84</td><td char="." align="char">0.62</td><td align="left">Enlarged</td><td align="left">Microadenoma</td><td align="left">n.a</td></tr><tr><td align="left">6</td><td align="left">Female</td><td char="." align="char">60</td><td char="." align="char">38</td><td align="left">3.2</td><td char="." align="char">1.01</td><td char="." align="char">14.1</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr></tbody></table>
###xml 757 762 753 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.d.</italic>
###xml 778 783 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.a.</italic>
###xml 620 798 616 794 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Normal range (median) for fT4: 10&#8211;24 (16.0) nmol/l, normal range for T3 1.1&#8211;3.0 (2.1) nmol/l, normal range for TSH 0.72&#8211;2.99 (1.25) mU/l.<italic> n.d.</italic> not determined,<italic> n.a.</italic> not applicable</p>
###xml 620 798 616 794 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Normal range (median) for fT4: 10&#8211;24 (16.0) nmol/l, normal range for T3 1.1&#8211;3.0 (2.1) nmol/l, normal range for TSH 0.72&#8211;2.99 (1.25) mU/l.<italic> n.d.</italic> not determined,<italic> n.a.</italic> not applicable</p></table-wrap-foot>
###xml 176 798 176 794 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="34">Clinical characteristics of the patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Gender</th><th align="left">Age</th><th align="left">fT<sub>4</sub> (nmol/l)</th><th align="left">T<sub>3</sub> (nmol/l)</th><th align="left">TSH (mU/l)</th><th align="left">&#945;-Subunit/TSH molar ratio</th><th align="left">Thyroid size</th><th align="left">Pituitary MRI</th><th align="left">Immunostaining adenoma</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">Male</td><td char="." align="char">73</td><td char="." align="char">31</td><td align="left">n.d.</td><td char="." align="char">4.30</td><td char="." align="char">3.99</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">TSH +</td></tr><tr><td align="left">2</td><td align="left">Male</td><td char="." align="char">44</td><td char="." align="char">47</td><td align="left">4.1</td><td char="." align="char">3.01</td><td char="." align="char">7.80</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">GH/TSH +/+</td></tr><tr><td align="left">3</td><td align="left">Female</td><td char="." align="char">38</td><td char="." align="char">36</td><td align="left">3.2</td><td char="." align="char">1.40</td><td char="." align="char">1.30</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">4</td><td align="left">Male</td><td char="." align="char">26</td><td char="." align="char">30</td><td align="left">4.2</td><td char="." align="char">3.35</td><td char="." align="char">0.93</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr><tr><td align="left">5</td><td align="left">Male</td><td char="." align="char">61</td><td char="." align="char">34</td><td align="left">3.3</td><td char="." align="char">5.84</td><td char="." align="char">0.62</td><td align="left">Enlarged</td><td align="left">Microadenoma</td><td align="left">n.a</td></tr><tr><td align="left">6</td><td align="left">Female</td><td char="." align="char">60</td><td char="." align="char">38</td><td align="left">3.2</td><td char="." align="char">1.01</td><td char="." align="char">14.1</td><td align="left">Enlarged</td><td align="left">Macroadenoma</td><td align="left">n.a</td></tr></tbody></table><table-wrap-foot><p textid="35">Normal range (median) for fT4: 10&#8211;24 (16.0) nmol/l, normal range for T3 1.1&#8211;3.0 (2.1) nmol/l, normal range for TSH 0.72&#8211;2.99 (1.25) mU/l.<italic> n.d.</italic> not determined,<italic> n.a.</italic> not applicable</p></table-wrap-foot></table-wrap>
###xml 40 48 <span type="species:ncbi:9606">patients</span>
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
Clinical and biochemical details of the patients are displayed in Table 1. One patient had severe acromegaly, and two other patients had slightly elevated IGF-I concentrations.Table 1Clinical characteristics of the patientsPatientGenderAgefT4 (nmol/l)T3 (nmol/l)TSH (mU/l)alpha-Subunit/TSH molar ratioThyroid sizePituitary MRIImmunostaining adenoma1Male7331n.d.4.303.99EnlargedMacroadenomaTSH +2Male44474.13.017.80EnlargedMacroadenomaGH/TSH +/+3Female38363.21.401.30EnlargedMacroadenoman.a4Male26304.23.350.93EnlargedMacroadenoman.a5Male61343.35.840.62EnlargedMicroadenoman.a6Female60383.21.0114.1EnlargedMacroadenoman.aNormal range (median) for fT4: 10-24 (16.0) nmol/l, normal range for T3 1.1-3.0 (2.1) nmol/l, normal range for TSH 0.72-2.99 (1.25) mU/l. n.d. not determined, n.a. not applicable
###end p 33
###begin p 34
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the patients
###end p 34
###begin p 35
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.d.</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.a.</italic>
Normal range (median) for fT4: 10-24 (16.0) nmol/l, normal range for T3 1.1-3.0 (2.1) nmol/l, normal range for TSH 0.72-2.99 (1.25) mU/l. n.d. not determined, n.a. not applicable
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 55 56 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 277 278 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 405 411 403 409 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 491 501 488 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 614 625 611 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 411 626 409 623 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38">Serum TSH response to 100&#160;&#956;g TRH. Note the subnormal response in all patients (<italic>Left panel</italic>). Effect of intravenous octreotide injection on TSH concentrations. Note the logarithmic scale of the abscissa (<italic>Right panel</italic>)</p>
###xml 411 626 409 623 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="38">Serum TSH response to 100&#160;&#956;g TRH. Note the subnormal response in all patients (<italic>Left panel</italic>). Effect of intravenous octreotide injection on TSH concentrations. Note the logarithmic scale of the abscissa (<italic>Right panel</italic>)</p></caption>
###xml 626 626 623 623 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig1_HTML" id="MO1"/>
###xml 405 626 403 623 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="38">Serum TSH response to 100&#160;&#956;g TRH. Note the subnormal response in all patients (<italic>Left panel</italic>). Effect of intravenous octreotide injection on TSH concentrations. Note the logarithmic scale of the abscissa (<italic>Right panel</italic>)</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig1_HTML" id="MO1"/></fig>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
Results of the i.v. 200 mug TRH test are shown in Fig. 1. Without exception the TSH increase was subnormal, ranging from 0 to 37%, with a mean of 15% (normal values exceeding 100%). An octreotide test (50 mug i.v.) was performed in 4 patients and the results are shown in Fig. 1. Acute inhibition of serum TSH concentration was remarkably similar among patients with a mean of 56%, ranging from 52 to 65%.Fig. 1Serum TSH response to 100 mug TRH. Note the subnormal response in all patients (Left panel). Effect of intravenous octreotide injection on TSH concentrations. Note the logarithmic scale of the abscissa (Right panel)
###end p 37
###begin p 38
###xml 80 90 79 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Left panel</italic>
###xml 203 214 202 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Right panel</italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Serum TSH response to 100 mug TRH. Note the subnormal response in all patients (Left panel). Effect of intravenous octreotide injection on TSH concentrations. Note the logarithmic scale of the abscissa (Right panel)
###end p 38
###begin p 39
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 749 755 749 755 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 755 918 755 918 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Serum TSH concentration profiles of 6 patients with a thyrotropinoma. The shaded zone represents the 95% confidence interval of 18 healthy matched control subjects</p>
###xml 755 918 755 918 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Serum TSH concentration profiles of 6 patients with a thyrotropinoma. The shaded zone represents the 95% confidence interval of 18 healthy matched control subjects</p></caption>
###xml 918 918 918 918 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig2_HTML" id="MO2"/>
###xml 749 918 749 918 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="40">Serum TSH concentration profiles of 6 patients with a thyrotropinoma. The shaded zone represents the 95% confidence interval of 18 healthy matched control subjects</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig2_HTML" id="MO2"/></fig>
###xml 918 924 918 924 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 924 1093 924 1091 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Results of the deconvolution analysis and approximate entropy calculation of the TSH profiles of 6 thyrotropinoma patients and 18 healthy controls. Data are mean&#160;&#177;&#160;SEM</p>
###xml 924 1093 924 1091 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Results of the deconvolution analysis and approximate entropy calculation of the TSH profiles of 6 thyrotropinoma patients and 18 healthy controls. Data are mean&#160;&#177;&#160;SEM</p></caption>
###xml 1093 1093 1091 1091 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig3_HTML" id="MO3"/>
###xml 918 1093 918 1091 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="41">Results of the deconvolution analysis and approximate entropy calculation of the TSH profiles of 6 thyrotropinoma patients and 18 healthy controls. Data are mean&#160;&#177;&#160;SEM</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig3_HTML" id="MO3"/></fig>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
###xml 438 446 <span type="species:ncbi:9606">patients</span>
###xml 586 594 <span type="species:ncbi:9606">patients</span>
###xml 793 801 <span type="species:ncbi:9606">patients</span>
###xml 1038 1046 <span type="species:ncbi:9606">patients</span>
Serum TSH concentration profiles of the 6 investigated patients are shown in Fig. 2 with the 95% confidence interval for TSH profiles of non-obese controls. Results of the deconvolution analysis and of approximate entropy of the TSH concentration profiles are shown in Fig. 3. TSH secretion in thyrotropinoma patients was characterized by increased hormone burst frequency. Furthermore, basal and pulsatile TSH secretion was increased in patients, but the secretion-burst shape (waveform) was unchanged, as indicated by the mode. TSH secretory regularity of the subordinate patterns in patients was markedly decreased (increased ApEn ratio). Regularity of the interburst intervals however, was unchanged as demonstrated by the Weibull gamma results.Fig. 2Serum TSH concentration profiles of 6 patients with a thyrotropinoma. The shaded zone represents the 95% confidence interval of 18 healthy matched control subjectsFig. 3Results of the deconvolution analysis and approximate entropy calculation of the TSH profiles of 6 thyrotropinoma patients and 18 healthy controls. Data are mean +/- SEM
###end p 39
###begin p 40
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Serum TSH concentration profiles of 6 patients with a thyrotropinoma. The shaded zone represents the 95% confidence interval of 18 healthy matched control subjects
###end p 40
###begin p 41
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Results of the deconvolution analysis and approximate entropy calculation of the TSH profiles of 6 thyrotropinoma patients and 18 healthy controls. Data are mean +/- SEM
###end p 41
###begin p 42
###xml 211 212 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 166 174 <span type="species:ncbi:9606">patients</span>
The estimated first component of the TSH half-life did not differ in patients and controls (24.5 +/- 2.5 vs. 22.2 +/- 2.2 min), but the slow component was shorter in patients (87.9 +/- 10.7 vs. 108 +/- 4.3 min, P = 0.048). This could denote reduced sialylation of tumoral TSH.
###end p 42
###begin p 43
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 622 629 622 629 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 629 671 629 671 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Growth hormone secretion in thyrotropinoma</p>
###xml 629 671 629 671 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Growth hormone secretion in thyrotropinoma</p></caption>
###xml 671 678 671 678 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient</th>
###xml 678 689 678 689 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (years)</th>
###xml 689 692 689 692 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sex</th>
###xml 692 709 692 709 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Fasting GH (mU/l)</th>
###xml 709 733 709 733 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GH secretion (mU/l/24&#160;h)</th>
###xml 733 746 733 745 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IGF-I (&#956;g/l)</th>
###xml 746 755 745 754 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IGF-I SDS</th>
###xml 755 765 754 764 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ApEn ratio</th>
###xml 671 765 671 764 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Patient</th><th align="left">Age (years)</th><th align="left">Sex</th><th align="left">Fasting GH (mU/l)</th><th align="left">GH secretion (mU/l/24&#160;h)</th><th align="left">IGF-I (&#956;g/l)</th><th align="left">IGF-I SDS</th><th align="left">ApEn ratio</th></tr>
###xml 671 765 671 764 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Patient</th><th align="left">Age (years)</th><th align="left">Sex</th><th align="left">Fasting GH (mU/l)</th><th align="left">GH secretion (mU/l/24&#160;h)</th><th align="left">IGF-I (&#956;g/l)</th><th align="left">IGF-I SDS</th><th align="left">ApEn ratio</th></tr></thead>
###xml 765 766 764 765 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 766 768 765 767 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">73</td>
###xml 768 772 767 771 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 772 775 771 774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.0</td>
###xml 775 778 774 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">169</td>
###xml 778 781 777 780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">228</td>
###xml 781 785 780 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.00</td>
###xml 785 790 784 789 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.483</td>
###xml 765 790 764 789 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">73</td><td align="left">Male</td><td align="left">2.0</td><td align="left">169</td><td align="left">228</td><td char="." align="char">3.00</td><td align="left">0.483</td></tr>
###xml 790 791 789 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 791 793 790 792 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">44</td>
###xml 793 797 792 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 797 800 796 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">142</td>
###xml 800 805 799 804 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17070</td>
###xml 805 808 804 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">550</td>
###xml 808 812 807 811 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10.4</td>
###xml 812 817 811 816 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.787</td>
###xml 790 817 789 816 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">44</td><td align="left">Male</td><td align="left">142</td><td align="left">17070</td><td align="left">550</td><td char="." align="char">10.4</td><td align="left">0.787</td></tr>
###xml 817 818 816 817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 818 820 817 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">38</td>
###xml 820 826 819 825 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 826 830 825 829 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.90</td>
###xml 830 833 829 832 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">205</td>
###xml 833 836 832 835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">274</td>
###xml 836 840 835 839 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2.23</td>
###xml 840 845 839 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.433</td>
###xml 817 845 816 844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">38</td><td align="left">Female</td><td align="left">1.90</td><td align="left">205</td><td align="left">274</td><td char="." align="char">2.23</td><td align="left">0.433</td></tr>
###xml 845 846 844 845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 846 848 845 847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">26</td>
###xml 848 852 847 851 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 852 856 851 855 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.11</td>
###xml 856 859 855 858 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">174</td>
###xml 859 862 858 861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">144</td>
###xml 862 866 861 865 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.02</td>
###xml 866 871 865 870 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.310</td>
###xml 845 871 844 870 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">26</td><td align="left">Male</td><td align="left">0.11</td><td align="left">174</td><td align="left">144</td><td char="." align="char">0.02</td><td align="left">0.310</td></tr>
###xml 871 872 870 871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 872 874 871 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">61</td>
###xml 874 878 873 877 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 878 882 877 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.20</td>
###xml 882 886 881 885 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.d.</td>
###xml 886 889 885 888 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">182</td>
###xml 889 893 888 892 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.80</td>
###xml 893 897 892 896 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.d.</td>
###xml 871 897 870 896 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5</td><td align="left">61</td><td align="left">Male</td><td align="left">0.20</td><td align="left">n.d.</td><td align="left">182</td><td char="." align="char">1.80</td><td align="left">n.d.</td></tr>
###xml 897 898 896 897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 898 900 897 899 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">60</td>
###xml 900 906 899 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 906 910 905 909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2.50</td>
###xml 910 912 909 911 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">81</td>
###xml 912 915 911 914 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">135</td>
###xml 915 919 914 918 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.16</td>
###xml 919 924 918 923 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.480</td>
###xml 897 924 896 923 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">60</td><td align="left">Female</td><td align="left">2.50</td><td align="left">81</td><td align="left">135</td><td char="." align="char">1.16</td><td align="left">0.480</td></tr>
###xml 924 932 923 931 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls</td>
###xml 932 942 931 941 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">30&#8211;68 (49)</td>
###xml 942 946 941 945 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Male</td>
###xml 946 962 945 961 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.02&#8211;1.10 (0.18)</td>
###xml 962 974 961 973 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">116&#8211;200 (45)</td>
###xml 974 986 973 985 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">75&#8211;185 (107)</td>
###xml 986 987 985 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 987 1006 986 1005 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.181&#8211;0.558 (0.330)</td>
###xml 924 1006 923 1005 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Controls</td><td align="left">30&#8211;68 (49)</td><td align="left">Male</td><td align="left">0.02&#8211;1.10 (0.18)</td><td align="left">116&#8211;200 (45)</td><td align="left">75&#8211;185 (107)</td><td char="." align="char">&#8211;</td><td align="left">0.181&#8211;0.558 (0.330)</td></tr>
###xml 1006 1014 1005 1013 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls</td>
###xml 1014 1024 1013 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">21&#8211;70 (37)</td>
###xml 1024 1030 1023 1029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Female</td>
###xml 1030 1046 1029 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.06&#8211;2.80 (0.56)</td>
###xml 1046 1058 1045 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">57&#8211;247 (123)</td>
###xml 1058 1070 1057 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">87&#8211;234 (143)</td>
###xml 1070 1071 1069 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 1071 1090 1070 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.260&#8211;0.514 (0.380)</td>
###xml 1006 1090 1005 1089 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Controls</td><td align="left">21&#8211;70 (37)</td><td align="left">Female</td><td align="left">0.06&#8211;2.80 (0.56)</td><td align="left">57&#8211;247 (123)</td><td align="left">87&#8211;234 (143)</td><td char="." align="char">&#8211;</td><td align="left">0.260&#8211;0.514 (0.380)</td></tr>
###xml 765 1090 764 1089 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">1</td><td align="left">73</td><td align="left">Male</td><td align="left">2.0</td><td align="left">169</td><td align="left">228</td><td char="." align="char">3.00</td><td align="left">0.483</td></tr><tr><td align="left">2</td><td align="left">44</td><td align="left">Male</td><td align="left">142</td><td align="left">17070</td><td align="left">550</td><td char="." align="char">10.4</td><td align="left">0.787</td></tr><tr><td align="left">3</td><td align="left">38</td><td align="left">Female</td><td align="left">1.90</td><td align="left">205</td><td align="left">274</td><td char="." align="char">2.23</td><td align="left">0.433</td></tr><tr><td align="left">4</td><td align="left">26</td><td align="left">Male</td><td align="left">0.11</td><td align="left">174</td><td align="left">144</td><td char="." align="char">0.02</td><td align="left">0.310</td></tr><tr><td align="left">5</td><td align="left">61</td><td align="left">Male</td><td align="left">0.20</td><td align="left">n.d.</td><td align="left">182</td><td char="." align="char">1.80</td><td align="left">n.d.</td></tr><tr><td align="left">6</td><td align="left">60</td><td align="left">Female</td><td align="left">2.50</td><td align="left">81</td><td align="left">135</td><td char="." align="char">1.16</td><td align="left">0.480</td></tr><tr><td align="left">Controls</td><td align="left">30&#8211;68 (49)</td><td align="left">Male</td><td align="left">0.02&#8211;1.10 (0.18)</td><td align="left">116&#8211;200 (45)</td><td align="left">75&#8211;185 (107)</td><td char="." align="char">&#8211;</td><td align="left">0.181&#8211;0.558 (0.330)</td></tr><tr><td align="left">Controls</td><td align="left">21&#8211;70 (37)</td><td align="left">Female</td><td align="left">0.06&#8211;2.80 (0.56)</td><td align="left">57&#8211;247 (123)</td><td align="left">87&#8211;234 (143)</td><td char="." align="char">&#8211;</td><td align="left">0.260&#8211;0.514 (0.380)</td></tr></tbody>
###xml 671 1090 671 1089 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Age (years)</th><th align="left">Sex</th><th align="left">Fasting GH (mU/l)</th><th align="left">GH secretion (mU/l/24&#160;h)</th><th align="left">IGF-I (&#956;g/l)</th><th align="left">IGF-I SDS</th><th align="left">ApEn ratio</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">73</td><td align="left">Male</td><td align="left">2.0</td><td align="left">169</td><td align="left">228</td><td char="." align="char">3.00</td><td align="left">0.483</td></tr><tr><td align="left">2</td><td align="left">44</td><td align="left">Male</td><td align="left">142</td><td align="left">17070</td><td align="left">550</td><td char="." align="char">10.4</td><td align="left">0.787</td></tr><tr><td align="left">3</td><td align="left">38</td><td align="left">Female</td><td align="left">1.90</td><td align="left">205</td><td align="left">274</td><td char="." align="char">2.23</td><td align="left">0.433</td></tr><tr><td align="left">4</td><td align="left">26</td><td align="left">Male</td><td align="left">0.11</td><td align="left">174</td><td align="left">144</td><td char="." align="char">0.02</td><td align="left">0.310</td></tr><tr><td align="left">5</td><td align="left">61</td><td align="left">Male</td><td align="left">0.20</td><td align="left">n.d.</td><td align="left">182</td><td char="." align="char">1.80</td><td align="left">n.d.</td></tr><tr><td align="left">6</td><td align="left">60</td><td align="left">Female</td><td align="left">2.50</td><td align="left">81</td><td align="left">135</td><td char="." align="char">1.16</td><td align="left">0.480</td></tr><tr><td align="left">Controls</td><td align="left">30&#8211;68 (49)</td><td align="left">Male</td><td align="left">0.02&#8211;1.10 (0.18)</td><td align="left">116&#8211;200 (45)</td><td align="left">75&#8211;185 (107)</td><td char="." align="char">&#8211;</td><td align="left">0.181&#8211;0.558 (0.330)</td></tr><tr><td align="left">Controls</td><td align="left">21&#8211;70 (37)</td><td align="left">Female</td><td align="left">0.06&#8211;2.80 (0.56)</td><td align="left">57&#8211;247 (123)</td><td align="left">87&#8211;234 (143)</td><td char="." align="char">&#8211;</td><td align="left">0.260&#8211;0.514 (0.380)</td></tr></tbody></table>
###xml 1348 1353 1347 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.d.</italic>
###xml 1369 1373 1368 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> SDS</italic>
###xml 1090 1398 1089 1397 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">GH secretion was calculated with deconvolution of the 24&#160;h serum GH concentration profiles. Control values were obtained from 26 male and 22 female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median.<italic> n.d.</italic> not determined,<italic> SDS</italic> standard deviation score</p>
###xml 1090 1398 1089 1397 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">GH secretion was calculated with deconvolution of the 24&#160;h serum GH concentration profiles. Control values were obtained from 26 male and 22 female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median.<italic> n.d.</italic> not determined,<italic> SDS</italic> standard deviation score</p></table-wrap-foot>
###xml 622 1398 622 1397 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="44">Growth hormone secretion in thyrotropinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Age (years)</th><th align="left">Sex</th><th align="left">Fasting GH (mU/l)</th><th align="left">GH secretion (mU/l/24&#160;h)</th><th align="left">IGF-I (&#956;g/l)</th><th align="left">IGF-I SDS</th><th align="left">ApEn ratio</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">73</td><td align="left">Male</td><td align="left">2.0</td><td align="left">169</td><td align="left">228</td><td char="." align="char">3.00</td><td align="left">0.483</td></tr><tr><td align="left">2</td><td align="left">44</td><td align="left">Male</td><td align="left">142</td><td align="left">17070</td><td align="left">550</td><td char="." align="char">10.4</td><td align="left">0.787</td></tr><tr><td align="left">3</td><td align="left">38</td><td align="left">Female</td><td align="left">1.90</td><td align="left">205</td><td align="left">274</td><td char="." align="char">2.23</td><td align="left">0.433</td></tr><tr><td align="left">4</td><td align="left">26</td><td align="left">Male</td><td align="left">0.11</td><td align="left">174</td><td align="left">144</td><td char="." align="char">0.02</td><td align="left">0.310</td></tr><tr><td align="left">5</td><td align="left">61</td><td align="left">Male</td><td align="left">0.20</td><td align="left">n.d.</td><td align="left">182</td><td char="." align="char">1.80</td><td align="left">n.d.</td></tr><tr><td align="left">6</td><td align="left">60</td><td align="left">Female</td><td align="left">2.50</td><td align="left">81</td><td align="left">135</td><td char="." align="char">1.16</td><td align="left">0.480</td></tr><tr><td align="left">Controls</td><td align="left">30&#8211;68 (49)</td><td align="left">Male</td><td align="left">0.02&#8211;1.10 (0.18)</td><td align="left">116&#8211;200 (45)</td><td align="left">75&#8211;185 (107)</td><td char="." align="char">&#8211;</td><td align="left">0.181&#8211;0.558 (0.330)</td></tr><tr><td align="left">Controls</td><td align="left">21&#8211;70 (37)</td><td align="left">Female</td><td align="left">0.06&#8211;2.80 (0.56)</td><td align="left">57&#8211;247 (123)</td><td align="left">87&#8211;234 (143)</td><td char="." align="char">&#8211;</td><td align="left">0.260&#8211;0.514 (0.380)</td></tr></tbody></table><table-wrap-foot><p textid="45">GH secretion was calculated with deconvolution of the 24&#160;h serum GH concentration profiles. Control values were obtained from 26 male and 22 female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median.<italic> n.d.</italic> not determined,<italic> SDS</italic> standard deviation score</p></table-wrap-foot></table-wrap>
###xml 1398 1404 1397 1403 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1404 1773 1403 1772 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Serum GH concentration profiles of 5 patients with a thyrotropinoma and 2 healthy representative controls (left upper panel, continuous line male subject, dashed line female subject). Note the difference in scales of the abscissa. The GH secretion patterns of patients #1&#8211;3 are clearly abnormal, while that of patient #6 only shows an increased basal (interpulse) level</p>
###xml 1404 1773 1403 1772 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Serum GH concentration profiles of 5 patients with a thyrotropinoma and 2 healthy representative controls (left upper panel, continuous line male subject, dashed line female subject). Note the difference in scales of the abscissa. The GH secretion patterns of patients #1&#8211;3 are clearly abnormal, while that of patient #6 only shows an increased basal (interpulse) level</p></caption>
###xml 1773 1773 1772 1772 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig4_HTML" id="MO4"/>
###xml 1398 1773 1397 1772 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="46">Serum GH concentration profiles of 5 patients with a thyrotropinoma and 2 healthy representative controls (left upper panel, continuous line male subject, dashed line female subject). Note the difference in scales of the abscissa. The GH secretion patterns of patients #1&#8211;3 are clearly abnormal, while that of patient #6 only shows an increased basal (interpulse) level</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig4_HTML" id="MO4"/></fig>
###xml 26 33 <span type="species:ncbi:9606">patient</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 265 272 <span type="species:ncbi:9606">patient</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 476 484 <span type="species:ncbi:9606">patients</span>
###xml 591 598 <span type="species:ncbi:9606">patient</span>
###xml 1441 1449 <span type="species:ncbi:9606">patients</span>
###xml 1664 1672 <span type="species:ncbi:9606">patients</span>
###xml 1714 1721 <span type="species:ncbi:9606">patient</span>
With the exception of one patient, GH secretion as also analyzed. The results are summarized in Table 2 and the GH concentration profiles are displayed in Fig. 4. Serum IGF-I concentrations and standard deviation scores were increased in patients 1-3, of whom only patient 2 had clinically active disease. However, patients 1 and 3 had (slightly) increased GH secretion, with respect to age and both had a definitely abnormal GH secretion profile, compared with the other two patients and examples of healthy controls (Fig. 4). Approximate entropy for GH secretion was only increased in the patient with active acromegaly.Table 2Growth hormone secretion in thyrotropinomaPatientAge (years)SexFasting GH (mU/l)GH secretion (mU/l/24 h)IGF-I (mug/l)IGF-I SDSApEn ratio173Male2.01692283.000.483244Male1421707055010.40.787338Female1.902052742.230.433426Male0.111741440.020.310561Male0.20n.d.1821.80n.d.660Female2.50811351.160.480Controls30-68 (49)Male0.02-1.10 (0.18)116-200 (45)75-185 (107)-0.181-0.558 (0.330)Controls21-70 (37)Female0.06-2.80 (0.56)57-247 (123)87-234 (143)-0.260-0.514 (0.380)GH secretion was calculated with deconvolution of the 24 h serum GH concentration profiles. Control values were obtained from 26 male and 22 female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median. n.d. not determined, SDS standard deviation scoreFig. 4Serum GH concentration profiles of 5 patients with a thyrotropinoma and 2 healthy representative controls (left upper panel, continuous line male subject, dashed line female subject). Note the difference in scales of the abscissa. The GH secretion patterns of patients #1-3 are clearly abnormal, while that of patient #6 only shows an increased basal (interpulse) level
###end p 43
###begin p 44
Growth hormone secretion in thyrotropinoma
###end p 44
###begin p 45
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.d.</italic>
###xml 279 283 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> SDS</italic>
GH secretion was calculated with deconvolution of the 24 h serum GH concentration profiles. Control values were obtained from 26 male and 22 female healthy subjects, who were investigated in a similar way. Data for controls are shown as the range and median. n.d. not determined, SDS standard deviation score
###end p 45
###begin p 46
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 310 317 <span type="species:ncbi:9606">patient</span>
Serum GH concentration profiles of 5 patients with a thyrotropinoma and 2 healthy representative controls (left upper panel, continuous line male subject, dashed line female subject). Note the difference in scales of the abscissa. The GH secretion patterns of patients #1-3 are clearly abnormal, while that of patient #6 only shows an increased basal (interpulse) level
###end p 46
###begin p 47
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 430 431 424 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 441 447 435 441 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 447 678 441 672 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Serum prolactin concentration profiles of 5 patients with a thyrotropinoma. The shaded area represents the 95% confidence interval obtained from 18 matched healthy controls. The lowest profile was obtained in the irradiated patient</p>
###xml 447 678 441 672 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Serum prolactin concentration profiles of 5 patients with a thyrotropinoma. The shaded area represents the 95% confidence interval obtained from 18 matched healthy controls. The lowest profile was obtained in the irradiated patient</p></caption>
###xml 678 678 672 672 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig5_HTML" id="MO5"/>
###xml 441 678 435 672 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="48">Serum prolactin concentration profiles of 5 patients with a thyrotropinoma. The shaded area represents the 95% confidence interval obtained from 18 matched healthy controls. The lowest profile was obtained in the irradiated patient</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig5_HTML" id="MO5"/></fig>
###xml 68 75 <span type="species:ncbi:9606">patient</span>
###xml 210 217 <span type="species:ncbi:9606">patient</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 358 366 <span type="species:ncbi:9606">patients</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 671 678 <span type="species:ncbi:9606">patient</span>
Serum prolactin concentration profiles are displayed in Fig. 5. One patient (#3) had increased levels throughout the 24-h cycle, and two others had raised levels during the daytime. In contrast, the irradiated patient had subnormal levels. The regularity of PRL patterns in patients was diminished compared with controls, as defined by higher ApEn ratios in patients (0.788 +/- 0.074, mean +/- SD) than controls (0.461 +/- 0.131, P < 0.001).Fig. 5Serum prolactin concentration profiles of 5 patients with a thyrotropinoma. The shaded area represents the 95% confidence interval obtained from 18 matched healthy controls. The lowest profile was obtained in the irradiated patient
###end p 47
###begin p 48
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 224 231 <span type="species:ncbi:9606">patient</span>
Serum prolactin concentration profiles of 5 patients with a thyrotropinoma. The shaded area represents the 95% confidence interval obtained from 18 matched healthy controls. The lowest profile was obtained in the irradiated patient
###end p 48
###begin p 49
###xml 222 223 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 275 276 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 1006 1012 994 1000 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1012 1121 1000 1109 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50">TSH and GH profiles of 2 patients with a thyrotropinoma. Note the similarity of the patterns of both hormones</p>
###xml 1012 1121 1000 1109 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="50">TSH and GH profiles of 2 patients with a thyrotropinoma. Note the similarity of the patterns of both hormones</p></caption>
###xml 1121 1121 1109 1109 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig6_HTML" id="MO6"/>
###xml 1006 1121 994 1109 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="50">TSH and GH profiles of 2 patients with a thyrotropinoma. Note the similarity of the patterns of both hormones</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig6_HTML" id="MO6"/></fig>
###xml 1121 1128 1109 1116 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1128 1199 1116 1183 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Cross-correlations between TSH, GH and &#945;-subunits in thyrotropinoma</p>
###xml 1128 1199 1116 1183 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Cross-correlations between TSH, GH and &#945;-subunits in thyrotropinoma</p></caption>
###xml 1199 1206 1183 1190 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient</th>
###xml 1206 1212 1190 1196 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TSH/GH</th>
###xml 1212 1230 1196 1210 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TSH/&#945;-subunits</th>
###xml 1230 1243 1210 1223 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">TSH/prolactin</th>
###xml 1199 1243 1183 1223 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Patient</th><th align="left">TSH/GH</th><th align="left">TSH/&#945;-subunits</th><th align="left">TSH/prolactin</th></tr>
###xml 1199 1243 1183 1223 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Patient</th><th align="left">TSH/GH</th><th align="left">TSH/&#945;-subunits</th><th align="left">TSH/prolactin</th></tr></thead>
###xml 1243 1244 1223 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 1244 1259 1224 1237 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.337&#160;&#177;&#160;0.083</td>
###xml 1259 1263 1237 1241 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.s.</td>
###xml 1263 1278 1241 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.350&#160;&#177;&#160;0.083</td>
###xml 1243 1278 1223 1254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">0.337&#160;&#177;&#160;0.083</td><td align="left">n.s.</td><td char="&#177;" align="char">0.350&#160;&#177;&#160;0.083</td></tr>
###xml 1278 1279 1254 1255 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 1279 1294 1255 1268 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.345&#160;&#177;&#160;0.084</td>
###xml 1294 1309 1268 1281 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.427&#160;&#177;&#160;0.084</td>
###xml 1309 1324 1281 1294 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.428&#160;&#177;&#160;0.083</td>
###xml 1278 1324 1254 1294 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">0.345&#160;&#177;&#160;0.084</td><td align="left">0.427&#160;&#177;&#160;0.084</td><td char="&#177;" align="char">0.428&#160;&#177;&#160;0.083</td></tr>
###xml 1324 1325 1294 1295 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 1325 1340 1295 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.279&#160;&#177;&#160;0.084</td>
###xml 1340 1344 1308 1312 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.s.</td>
###xml 1344 1359 1312 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.190&#160;&#177;&#160;0.085</td>
###xml 1324 1359 1294 1325 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">0.279&#160;&#177;&#160;0.084</td><td align="left">n.s.</td><td char="&#177;" align="char">0.190&#160;&#177;&#160;0.085</td></tr>
###xml 1359 1360 1325 1326 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 1360 1364 1326 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.s.</td>
###xml 1364 1379 1330 1343 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0.320&#160;&#177;&#160;0.121</td>
###xml 1379 1394 1343 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.385&#160;&#177;&#160;0.083</td>
###xml 1359 1394 1325 1356 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">n.s.</td><td align="left">0.320&#160;&#177;&#160;0.121</td><td char="&#177;" align="char">0.385&#160;&#177;&#160;0.083</td></tr>
###xml 1394 1395 1356 1357 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 1395 1399 1357 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.s.</td>
###xml 1399 1403 1361 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">n.s.</td>
###xml 1403 1418 1365 1378 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="&#xB1;" align="char">0.405&#160;&#177;&#160;0.083</td>
###xml 1394 1418 1356 1378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">n.s.</td><td align="left">n.s.</td><td char="&#177;" align="char">0.405&#160;&#177;&#160;0.083</td></tr>
###xml 1243 1418 1223 1378 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">1</td><td align="left">0.337&#160;&#177;&#160;0.083</td><td align="left">n.s.</td><td char="&#177;" align="char">0.350&#160;&#177;&#160;0.083</td></tr><tr><td align="left">2</td><td align="left">0.345&#160;&#177;&#160;0.084</td><td align="left">0.427&#160;&#177;&#160;0.084</td><td char="&#177;" align="char">0.428&#160;&#177;&#160;0.083</td></tr><tr><td align="left">3</td><td align="left">0.279&#160;&#177;&#160;0.084</td><td align="left">n.s.</td><td char="&#177;" align="char">0.190&#160;&#177;&#160;0.085</td></tr><tr><td align="left">4</td><td align="left">n.s.</td><td align="left">0.320&#160;&#177;&#160;0.121</td><td char="&#177;" align="char">0.385&#160;&#177;&#160;0.083</td></tr><tr><td align="left">6</td><td align="left">n.s.</td><td align="left">n.s.</td><td char="&#177;" align="char">0.405&#160;&#177;&#160;0.083</td></tr></tbody>
###xml 1199 1418 1183 1378 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">TSH/GH</th><th align="left">TSH/&#945;-subunits</th><th align="left">TSH/prolactin</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">0.337&#160;&#177;&#160;0.083</td><td align="left">n.s.</td><td char="&#177;" align="char">0.350&#160;&#177;&#160;0.083</td></tr><tr><td align="left">2</td><td align="left">0.345&#160;&#177;&#160;0.084</td><td align="left">0.427&#160;&#177;&#160;0.084</td><td char="&#177;" align="char">0.428&#160;&#177;&#160;0.083</td></tr><tr><td align="left">3</td><td align="left">0.279&#160;&#177;&#160;0.084</td><td align="left">n.s.</td><td char="&#177;" align="char">0.190&#160;&#177;&#160;0.085</td></tr><tr><td align="left">4</td><td align="left">n.s.</td><td align="left">0.320&#160;&#177;&#160;0.121</td><td char="&#177;" align="char">0.385&#160;&#177;&#160;0.083</td></tr><tr><td align="left">6</td><td align="left">n.s.</td><td align="left">n.s.</td><td char="&#177;" align="char">0.405&#160;&#177;&#160;0.083</td></tr></tbody></table>
###xml 1507 1512 1467 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.s.</italic>
###xml 1418 1528 1378 1488 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Cross-correlations were calculated after removing autocorrelations by first differencing.<italic> n.s.</italic> non-significant</p>
###xml 1418 1528 1378 1488 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Cross-correlations were calculated after removing autocorrelations by first differencing.<italic> n.s.</italic> non-significant</p></table-wrap-foot>
###xml 1121 1528 1109 1488 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="51">Cross-correlations between TSH, GH and &#945;-subunits in thyrotropinoma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">TSH/GH</th><th align="left">TSH/&#945;-subunits</th><th align="left">TSH/prolactin</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">0.337&#160;&#177;&#160;0.083</td><td align="left">n.s.</td><td char="&#177;" align="char">0.350&#160;&#177;&#160;0.083</td></tr><tr><td align="left">2</td><td align="left">0.345&#160;&#177;&#160;0.084</td><td align="left">0.427&#160;&#177;&#160;0.084</td><td char="&#177;" align="char">0.428&#160;&#177;&#160;0.083</td></tr><tr><td align="left">3</td><td align="left">0.279&#160;&#177;&#160;0.084</td><td align="left">n.s.</td><td char="&#177;" align="char">0.190&#160;&#177;&#160;0.085</td></tr><tr><td align="left">4</td><td align="left">n.s.</td><td align="left">0.320&#160;&#177;&#160;0.121</td><td char="&#177;" align="char">0.385&#160;&#177;&#160;0.083</td></tr><tr><td align="left">6</td><td align="left">n.s.</td><td align="left">n.s.</td><td char="&#177;" align="char">0.405&#160;&#177;&#160;0.083</td></tr></tbody></table><table-wrap-foot><p textid="52">Cross-correlations were calculated after removing autocorrelations by first differencing.<italic> n.s.</italic> non-significant</p></table-wrap-foot></table-wrap>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
###xml 824 832 <span type="species:ncbi:9606">patients</span>
###xml 1037 1045 <span type="species:ncbi:9606">patients</span>
We also investigated cross-correlations between 24-h TSH concentrations and each of GH, alpha-subunit and PRL. Profiles of the serum concentrations of GH and TSH in two patients were rather similar, as illustrated in Fig. 6. The cross-correlation outcomes are shown in Table 3. Three patients had a highly significant correlation between serum TSH and GH concentrations. In contrast, in healthy controls no correlation between these two hormones could be demonstrated. In two of 5 patients a significant correlation could be demonstrated between serum TSH and alpha-subunits concentrations, where an almost 100% concordance was expected when alpha-subunits are truly co-secreted with TSH. Unfortunately, we have no comparable data in controls subjects. The cross-correlation between TSH and prolactin was significant in all patients. However, two-thirds of healthy controls also showed a significant correlation between these two hormones, with a median correlation coefficient of 0.300, range 0.176-0.360.Fig. 6TSH and GH profiles of 2 patients with a thyrotropinoma. Note the similarity of the patterns of both hormonesTable 3Cross-correlations between TSH, GH and alpha-subunits in thyrotropinomaPatientTSH/GHTSH/alpha-subunitsTSH/prolactin10.337 +/- 0.083n.s.0.350 +/- 0.08320.345 +/- 0.0840.427 +/- 0.0840.428 +/- 0.08330.279 +/- 0.084n.s.0.190 +/- 0.0854n.s.0.320 +/- 0.1210.385 +/- 0.0836n.s.n.s.0.405 +/- 0.083Cross-correlations were calculated after removing autocorrelations by first differencing. n.s. non-significant
###end p 49
###begin p 50
###xml 25 33 <span type="species:ncbi:9606">patients</span>
TSH and GH profiles of 2 patients with a thyrotropinoma. Note the similarity of the patterns of both hormones
###end p 50
###begin p 51
Cross-correlations between TSH, GH and alpha-subunits in thyrotropinoma
###end p 51
###begin p 52
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> n.s.</italic>
Cross-correlations were calculated after removing autocorrelations by first differencing. n.s. non-significant
###end p 52
###begin p 53
###xml 243 244 235 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 196 204 <span type="species:ncbi:9606">patients</span>
Cross-ApEn ratios for TSH and GH were similar in patients and controls (0.716 +/- 0.085 in patients vs. 0.678 +/- 0.018 in controls), but cross-ApEn ratios for TSH and prolactin were increased in patients (0.774 +/- 0.041 vs. 0.547 +/- 0.022, P = 0.001), denoting significant loss of pattern synchrony.
###end p 53
###begin p 54
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 300 301 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 382 383 370 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 242 250 <span type="species:ncbi:9606">patients</span>
All patients had significant diurnal TSH and PRL rhythms. For TSH the acrophase of the rhythm was shifted (time-delayed) from 2.83 to 5.58 h (P = 0.02) and for PRL from 4.36 to 6.20 h (P = 0.07). For TSH amplitudes were 0.83 +/- 0.29 mU/l in patients and 0.54 +/- 0.25 mU/l in controls (mean +/- SD, P = 0.09), and for PRL 1.43 +/- 0.44 mug/l and 0.97 +/- 0.60 mug/l, respectively (P = 0.09).
###end p 54
###begin title 55
Effect of octreotide treatment
###end title 55
###begin p 56
###xml 900 901 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 1160 1166 1155 1161 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 1166 1343 1161 1338 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="57">Effect of octreotide treatment on fasting morning hormone concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum free thyroxine. Note the logarithmic scale for GH</p>
###xml 1166 1343 1161 1338 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="57">Effect of octreotide treatment on fasting morning hormone concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum free thyroxine. Note the logarithmic scale for GH</p></caption>
###xml 1343 1343 1338 1338 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11102_2008_159_Fig7_HTML" id="MO7"/>
###xml 1160 1343 1155 1338 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="57">Effect of octreotide treatment on fasting morning hormone concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum free thyroxine. Note the logarithmic scale for GH</p></caption><graphic position="anchor" xlink:href="11102_2008_159_Fig7_HTML" id="MO7"/></fig>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 92 99 <span type="species:ncbi:9606">patient</span>
###xml 135 142 <span type="species:ncbi:9606">patient</span>
###xml 429 436 <span type="species:ncbi:9606">patient</span>
###xml 504 511 <span type="species:ncbi:9606">patient</span>
###xml 1097 1105 <span type="species:ncbi:9606">patients</span>
###xml 1142 1150 <span type="species:ncbi:9606">patients</span>
###xml 1244 1252 <span type="species:ncbi:9606">patients</span>
Five of the six patients received octreotide as medical treatment, 4 as octreotide LAR. One patient (#5) refused medication. One other patient (#1) was treated preoperatively with octreotide (200 mug t.i.d.) for 3 months. Subsequently, he underwent transsphenoidal surgery, but had still (slightly) increased GH and IGF-I concentrations afterwards although TSH and thyroid hormone concentrations became and remained normal. This patient was treated with octreotide for the persisting GH excess. Finally, patient #6 had also a toxic nodular goiter, for which she was treated with radioactive iodine and suppressive thyroid medication after initial failure of normalization of thyroid hormone concentrations associated with (moderate) decrease of already low TSH levels. The effect of octreotide on fasting morning thyroxine, TSH, GH, IGF-I, prolactin and alpha-subunit concentrations is shown in Fig. 7. Free thyroxine concentrations normalized in all but one with a parallel reduction of TSH and also of IGF-I, GH and prolactin concentrations. The size of the adenoma on MRI decreased slightly in patients #3 and 4, but remained unchanged in patients #2 and 6.Fig. 7Effect of octreotide treatment on fasting morning hormone concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum free thyroxine. Note the logarithmic scale for GH
###end p 56
###begin p 57
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Effect of octreotide treatment on fasting morning hormone concentrations in 5 patients with a thyrotropinoma. fT4 denotes serum free thyroxine. Note the logarithmic scale for GH
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
###xml 385 392 <span type="species:ncbi:9606">patient</span>
This cohort of patients with a TSH-secreting pituitary adenoma maintained a high TSH pulse frequency with normal pulsing variability, increased basal and pulsatile TSH release and decreased secretory-pattern regularity. In addition, three of five patients also showed increased GH secretion, although clinically manifest in only one. Sustained increased PRL levels were present in one patient.
###end p 59
###begin p 60
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Previous investigations have demonstrated that frequent hormone pulses constitute feature of all endocrine adenomas, including somatotropinomas, prolactinomas, corticotropinomas and also hormone-secreting adrenal adenomas [8-10, 17]. This common finding among diverse tumors suggests that the cause of increased pulsatility is not primarily mediated via signaling of increased frequency of stimulatory peptides or neurotransmitters, but rather is an intrinsic feature of the adenoma per se.
###end p 60
###begin p 61
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1026 1028 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1627 1628 1627 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">.</italic>
###xml 1751 1752 1748 1749 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1829 1831 1826 1828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1833 1835 1830 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Stability of the Weibull gamma parameter indicated that the increased TSH pulse frequency in patients is not associated with altered variability in length of interpulse intervals. Conversely, the elevated Weibull lambda parameter confirms increased TSH pulsing. The other remarkable finding was the decreased regularity of TSH secretory patterns as revealed by the increased ApEn. Approximate entropy has been investigated in a variety of altered feed-forward and feed-back states in healthy individuals, for instance in the somatotropic axis in healthy subjects during GHRH or GHRP-2 infusions and pegvisomant administration [23-25]. Increased stimulation of somatotropes is accompanied by decreased regularity (increased ApEn), and decreased IGF-I feedback by blocking the GH signal with the GH-receptor blocking drug, pegvisomant, is also associated with decreased orderliness of GH secretion. Such studies indicate that higher ApEn reflects elevated feed-forward and reduced feed-back signaling of the studied system [15, 25]. For TSH comparable conditions of diminished feedback would be primary hypothyroidism and thyroid hormone resistance, which have not been studied. In contrast, endocrine tumors are generally not well regulated by exogenous stimuli (with the possible exceptions of some GHRH-secreting carcinoid tumors and ectopic CRH-producing tumors), although diminished feedback may be present, as observed in corticotropinomas (glucocorticoids), somatotropinoma (IGF-I) and parathyroid adenomas (calcium). Thus, increased TSH ApEn in thyrotropinomas likely reflects disorganized secretion from the tumor per se. Aberrant alternative splicing of thyroid hormone-receptor beta2 mRNA encoding a thyroid hormone receptor variant lacking T3 binding activity might in principle also contribute to irregular secretion [26, 27].
###end p 61
###begin p 62
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Co-secretion of GH and prolactin is found in about one-third of patients with a thyrotropinoma [7]. Up to 16% of patients co-secrete GH and 11% prolactin, while co-secretion of gonadotropins is rare (about 1%). Immunohistochemical studies report an even larger incidence of co-expression of GH and PRL mRNA in the thyrotrope tumors, suggesting that either these hormones are not secreted in quantities leading to clinical disease and furthermore that the tumor cell is derived from a common precursor cell [28-31].
###end p 62
###begin p 63
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 710 711 710 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 714 715 714 715 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 13 21 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 646 654 <span type="species:ncbi:9606">patients</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
Although all patients with a TSH-secreting adenoma secrete relatively excessive amounts of thyroid hormones, the TSH concentration in patients varies from normal to grossly elevated, in contrast with other hormone-secreting pituitary adenomas, e.g. somatotropinomas and corticotropinomas. This observation has been explained by increased biological activity of less acidic post-glycosylation isoforms of TSH [32]. Some preservation of feedback at the pituitary level cannot be ruled out, although it has not been studied in detail. Indeed, in our case series only two patients had an increased mean TSH concentration (Fig. 2), although the other patients should have had suppressed TSH levels due to elevated T4 (T3) concentrations. Terminal sialylation of TSH can reduce its metabolic clearance, and indeed we found a 25% increase of the second component of the TSH half-life in our patients.
###end p 63
###begin p 64
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1149 1150 1133 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
###xml 1117 1125 <span type="species:ncbi:9606">patients</span>
The other major cause of central hyperthyroidism is thyroid hormone resistance. This syndrome is not associated with a pituitary tumor [33]. The TRH test in this condition is normal or hyperresponsive in contrast to the blunted TSH response in thyrotropinomas. In addition, patients with this disorder do not respond to somatostatin analog therapy [34]. The results of the TRH and octreotide tests are relevant and important in this context, because we have no histological proof for a thyrotropinoma in 4 of the 6 patients, although the presence of a (micro) adenoma would not favor a resistance syndrome. Other indirect methods to discriminate between thyroid hormone resistance and thyrotropinomas are the dissociated effects of TRH on TSH and alpha-subunits and the molar ratio of alpha-subunits and TSH. Taking into account that one of the patients was postmenopausal (although she had a normal alpha-subunit level) only two of our patients had an increased ratio. However, recent data suggest that high levels of alpha-subunit and an increased ratio are not invariably present and are actually normal in 20% of patients with a thyrotropinoma [1].
###end p 64
###begin p 65
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 387 394 <span type="species:ncbi:9606">patient</span>
Treatment modalities of thyrotropinomas include transsphenoidal surgery and/or (primary) medical treatment. Generally, surgery may cure up to 50-80% and therapy with long-acting somatostatin analogues may be effective in about 80% of patients [35-41]. In line with the literature fasting hormone levels (TSH, fT4, GH, IGF-I and prolactin) decreased in all patients (except for T4 in the patient with a toxic nodular goiter) during treatment with octreotide-LAR, thus demonstrating that the suppressive effect was not restricted to TSH secretion. Rare subjects have had both primary hyperthyroidism and central hyperthyroidism [36, 42]. Indeed, medical therapy failure aimed at TSH normalization may lead to the correct (additional) diagnosis.
###end p 65
###begin p 66
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
A limitation of the study is the small number of investigated patients with this rare disorder. In addition, we could only evaluate patients with TSH concentrations mostly within the normal range. Therefore, the present conclusions cannot be extrapolated to patients with much higher TSH levels.
###end p 66
###begin p 67
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 272 279 <span type="species:ncbi:9606">patient</span>
###xml 503 511 <span type="species:ncbi:9606">patients</span>
###xml 545 553 <span type="species:ncbi:9606">patients</span>
###xml 589 596 <span type="species:ncbi:9606">patient</span>
###xml 695 702 <span type="species:ncbi:9606">patient</span>
###xml 745 752 <span type="species:ncbi:9606">patient</span>
All our patients had a significant diurnal TSH rhythm with a mean phase delay of 2.7 h with unchanged amplitude. Few TSH serum profiles of patients with TSH-secreting adenomas have been published, but not of co-secreted GH and prolactin. Samuels et al. described a female patient with a TSH-secreting tumor, who had pulsatile TSH secretion, but no diurnal rhythm when monitored by 15-min sampling for 24-h [43]. Later, the same group reported absent diurnal variation of TSH in two other thyrotropinoma patients [44]. In another report two male patients were sampled at 2-h intervals: one patient showed a clear diurnal rhythm with a significant phase delay, as observed here, whereas the other patient had no clear rhythm [45]. Finally, a male patient was described with no apparent TSH rhythm, but the rhythm was restored during treatment with bromocriptine and octreotide. Paradoxically, the mean 24-h TSH concentration increased during medical treatment [46].
###end p 67
###begin p 68
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 1188 1190 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">47</xref>
###xml 13 20 <span type="species:ncbi:9606">patient</span>
###xml 95 102 <span type="species:ncbi:9606">patient</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 673 681 <span type="species:ncbi:9606">patients</span>
###xml 726 734 <span type="species:ncbi:9606">patients</span>
###xml 889 897 <span type="species:ncbi:9606">patients</span>
This limited patient series also demonstrates abnormalities in GH and prolactin secretion. One patient had overt acromegaly, and two others exhibited a definitely abnormal GH secretion pattern (Fig. 5), which resembled the TSH pattern. In addition, the results of the deconvolution analysis also revealed (moderately in two) increased GH secretion in 3 patients, consistent with a high incidence of GH excess. Indeed, IGF-I concentrations and the SD scores were elevated in these patients, but clinical symptoms were not apparent in two individuals. Other indirect biochemical clues of hormone cosecretion were significant cross-correlations between TSH and GH (3 out of 5 patients), and between TSH and prolactin (5 out of 5 patients) and the phase delay of TSH and PRL diurnal rhythms. Somewhat unexpectedly, a significant correlation between TSH and alpha-subunit was found in only two patients, one of whom had clinically severe acromegaly. The lack of correlation between TSH and alpha-subunit suggests that their secretion is not coordinately regulated in the thyrotrope or that some tumors may consist of a mixed population of thyrotropes and purely alpha-subunit-secreting cells [47].
###end p 68
###begin p 69
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1078 1080 1078 1080 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">53</xref>
Recent histological studies of the pituitary gland have revealed that growth hormone-secreting cells form a large-scale network. This functional three-dimensional GH-network consists of cells linked with focal adherent junctions, shows robustness across the lifespan despite reversible plasticity of the architecture, for instance at puberty when GH secretion is amplified [48]. Such a network can produce rapid and synchronized hormone pulses in response to physiological needs. If a similar network exists for thyrotropes, disruptions of functional organization in TSH adenomas could explain disorganized TSH secretion, as here observed with increased ApEn in concert with the increased burst frequency. In addition, folliculo-stellate cells might be involved coordinating hormone secretion in the three-dimensional network [49]. These cells participate in scavenger activity, paracrine regulation of endocrine cells, as a source of stem cells and large-scale intercellular communication by means of long cytoplasmatic processes and gap junctions that mediate intercellular Ca2+ waves [49-53]. Observed loss of folliculostellate cells might thus contribute to abnormal hormone secretion patterns by pituitary adenomas.
###end p 69
###begin p 70
In summary, TSH secretion by thyrotropinomas is characterized by increased pulse frequency with normal interpulse variability, decreased secretory regularity, enhanced hormone release and a delayed phase of the diurnal rhythm. In addition, GH and prolactin secretion also exhibit various abnormalities, ranging from decreased regularity to overt hypersecretion. We hypothesize that aberrant secretory characteristics are caused by histological and cellular alterations of the network of thyrotrophic tumor cells.
###end p 70
###begin title 71
Open Access
###end title 71
###begin p 72
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 72
###begin title 73
References
###end title 73
###begin article-title 74
Circadian changes in pulsatile TSH release in primary hypothyroidism
###end article-title 74
###begin article-title 75
Pituitary-thyroid axis in critical illness
###end article-title 75
###begin article-title 76
Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues
###end article-title 76
###begin article-title 77
Pulsatile secretion of thyrotropin during fasting: a decrease of thyrotropin pulse amplitude
###end article-title 77
###begin article-title 78
###xml 105 110 <span type="species:ncbi:9606">women</span>
Spontaneous diurnal TSH secretion is enhanced in proportion to circulating leptin in obese premenopausal women
###end article-title 78
###begin article-title 79
Thyrotropin-secreting pituitary tumors
###end article-title 79
###begin article-title 80
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease
###end article-title 80
###begin article-title 81
Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas
###end article-title 81
###begin article-title 82
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Growth hormone secretion in recently operated acromegalic patients
###end article-title 82
###begin article-title 83
Physiological control of pituitary hormone secretory-burst mass, frequency and waveform: a statistical formulation and analysis
###end article-title 83
###begin article-title 84
A new look at the statistical model identification
###end article-title 84
###begin article-title 85
Irregularity and asynchrony in biologic network signals
###end article-title 85
###begin article-title 86
Enhanced basal and disorderly growth hormone secretion distinguish acromegalic from normal pulsatile growth hormone release
###end article-title 86
###begin article-title 87
###xml 100 106 <span type="species:ncbi:9606">humans</span>
Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans
###end article-title 87
###begin article-title 88
Hormone pulsatility discrimination via coarse and short time sampling
###end article-title 88
###begin article-title 89
Irregular and frequent cortisol secretory episodes with preserved diurnal rhythmicity in primary adrenal Cushing's syndrome
###end article-title 89
###begin article-title 90
###xml 100 105 <span type="species:ncbi:9606">human</span>
Analysis of bidirectional pattern synchrony of concentration-secretion pairs: implementation in the human testicular and adrenal axes
###end article-title 90
###begin article-title 91
###xml 52 57 <span type="species:ncbi:9606">human</span>
Joint synchrony of reciprocal hormonal signaling in human paradigms of both ACTH excess and cortisol depletion
###end article-title 91
###begin article-title 92
Hypothesis testing of the aging male gonadal axis via a biomathematical construct
###end article-title 92
###begin article-title 93
Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males
###end article-title 93
###begin article-title 94
Twenty-four hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts
###end article-title 94
###begin article-title 95
###xml 55 60 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:9606">women</span>
Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states
###end article-title 95
###begin article-title 96
###xml 247 250 <span type="species:ncbi:9606">men</span>
###xml 255 260 <span type="species:ncbi:9606">women</span>
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
###end article-title 96
###begin article-title 97
###xml 273 278 <span type="species:ncbi:9606">women</span>
###xml 283 286 <span type="species:ncbi:9606">men</span>
Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-Peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men
###end article-title 97
###begin article-title 98
Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance
###end article-title 98
###begin article-title 99
Somatic mutation of TR beta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor
###end article-title 99
###begin article-title 100
GH and PRL gene expression by nonradioisotopic in situ hybridization in TSH-secreting pituitary adenomas
###end article-title 100
###begin article-title 101
Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment
###end article-title 101
###begin article-title 102
An abnormality of thyroid hormone receptor expression may explain abnormal thyrotropin hormone production in thyrotropin-secreting pituitary tumors
###end article-title 102
###begin article-title 103
Thyroid-stimulating hormone pituitary adenomas
###end article-title 103
###begin article-title 104
Variable biological activity of thyroid-stimulating hormone
###end article-title 104
###begin article-title 105
Resistance to thyroid hormone
###end article-title 105
###begin article-title 106
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Different responses to chronic somatostatin analogues in patients with central hyperthyroidism
###end article-title 106
###begin article-title 107
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health
###end article-title 107
###begin article-title 108
Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment
###end article-title 108
###begin article-title 109
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients
###end article-title 109
###begin article-title 110
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas: a follow-up of 52 patients
###end article-title 110
###begin article-title 111
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog Lanreotide
###end article-title 111
###begin article-title 112
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Efficacy of the long-acting octreotide formulation (Octreotide-Lar) in patients with thyrotropin-secreting pituitary adenomas
###end article-title 112
###begin article-title 113
Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature
###end article-title 113
###begin article-title 114
###xml 46 53 <span type="species:ncbi:9606">patient</span>
Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause-effect relationship
###end article-title 114
###begin article-title 115
Clinical and molecular studies of a thyrotropin-secreting pituitary adenoma
###end article-title 115
###begin article-title 116
Pulsatile glycoprotein hormone secretion in glycoprotein-producing pituitary tumors
###end article-title 116
###begin article-title 117
Thyrotropin-secreting pituitary adenomas: report of seven cases
###end article-title 117
###begin article-title 118
###xml 51 58 <span type="species:ncbi:9606">patient</span>
Pulsatile thyrotropin and prolactin secretion in a patient with a mixed thyrotropin- and prolactin-secreting pituitary adenoma
###end article-title 118
###begin article-title 119
Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another one cosecreting alpha-subunit and thyrotropin
###end article-title 119
###begin article-title 120
Revealing the large-scale network organization of growth hormone-secreting cells
###end article-title 120
###begin article-title 121
Paracrinicity: the story of 30 years of cellular pituitary crosstalk
###end article-title 121
###begin article-title 122
An insight to pituitary folliculo-stellate cells
###end article-title 122
###begin article-title 123
###xml 32 37 <span type="species:ncbi:9606">human</span>
Folliculo-stellate cells of the human pituitary: a type of adult stem cell?
###end article-title 123
###begin article-title 124
###xml 40 43 <span type="species:ncbi:10116">rat</span>
###xml 170 173 <span type="species:ncbi:10116">rat</span>
Intercellular communications within the rat anterior pituitary XI: an immunohistochemical study of distributions of S-100 positive cells in the anterior pituitary of the rat
###end article-title 124
###begin article-title 125
###xml 57 62 <span type="species:ncbi:9606">human</span>
Immunohistochemical study of folliculo-stellate cells in human pituitary adenomas
###end article-title 125

